Patients-Show-Strong-Preference-for-New-Subcutaneous-Ocrelizumab-Formulation-UVA-Study

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawOcrelizumab-hyaluronidase-ocsq (Ocrevus Zunovo, Genentech), the recently approved subcutaneous formulation of the multiple sclerosis (MS) drug ocrelizumab, is strongly preferred by patients over the standard ocrelizumab infusion, according to new data presented at the NASP 2025 Annual Meeting, in Denver.Researchers from UVA Health implemented a pharmacy-led, clinic-based protocol for ocrelizumab-hyaluronidase-